JONATHAN SILVERSTEIN

Jonathan Silverstein stands as a pivotal figure at OrbiMed, one of the world's foremost healthcare-dedicated investment firms. As a Senior Managing Partner and Co-Head of Private Equity, he plays a critical leadership role in shaping OrbiMed's extensive private equity portfolio. His expertise is instrumental in identifying and cultivating groundbreaking companies across the global healthcare landscape, driving innovation and delivering significant value.

Silverstein's investment focus at OrbiMed is broad yet deeply specialized within the healthcare sector. He targets private equity opportunities across various sub-sectors, including cutting-edge biotechnology firms, established pharmaceutical companies, innovative medical device manufacturers, and advanced diagnostics providers. His strategic vision helps OrbiMed back companies that are developing novel therapies, improving patient outcomes, and addressing unmet medical needs worldwide. Through growth equity, venture capital, and buyout strategies, he supports companies from early-stage development through commercialization, helping them scale and achieve their full potential.

Jonathan Silverstein's distinguished career at OrbiMed began in 1999, marking over two decades of dedicated service and leadership within the firm. Prior to joining OrbiMed, he honed his financial acumen and industry insights at The Wilkerson Group, a specialized investment banking firm focused exclusively on the healthcare sector. This foundational experience provided him with a deep understanding of healthcare market dynamics and investment strategies. Academically, Silverstein holds an MBA from Harvard Business School, a testament to his strong business and financial education, complemented by a Bachelor of Arts degree from the University of Pennsylvania.

Throughout his tenure, Silverstein has been instrumental in OrbiMed's mission to invest globally across the full spectrum of healthcare companies. While specific individual investments are often part of a broader fund strategy, his leadership in private equity has undoubtedly contributed to the success of numerous portfolio companies that have brought life-changing innovations to market. His work ensures that capital is directed towards enterprises poised to make a substantial impact on global health, from developing new cancer treatments to creating advanced surgical tools. Jonathan Silverstein's commitment to fostering innovation and growth within healthcare underscores his significant influence in the investment community and his dedication to advancing medical science and patient care.